---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-129531"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:29:03.087612+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC

## Summary
- $125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.
- Pro forma cash into 2H 2027 funds through first ORIC-944 Phase 3 registrational trial primary endpoint.
- ORIC-944 + AR inhibitor achieved 59% PSA50 (10/17), 47% confirmed PSA50, and 24% PSA90 (4/17) in heavily pretreated mCRPC.
- Safety mostly Grade 1/2 GI events (diarrhea 53%, one Grade 3); no Grade 4/5 treatment-related AEs.
- Phase 1b dose optimization in 2H 2025; first global Phase 3 registrational trial expected to start in 1H 2026.

## SEC filing metadata
- accession: 0001193125-25-129531
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312525129531/0001193125-25-129531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312525129531/d911818d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-129531
- JSON: https://secwatch.observer/filing/0001193125-25-129531.json
- Plain text: https://secwatch.observer/filing/0001193125-25-129531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.